WuXi AppTec pitches integrated model for protein degrader development

WuXi AppTec outlined an end-to-end approach for targeted protein degrader programs, arguing that discovery biology, medicinal chemistry, DMPK, and manufacturing need to stay connected as candidates advance. The company says the model is meant to cut friction and help programs in oncology, immunology, and other areas move faster toward the clinic.

Why it matters: - Targeted protein degradation is expanding across oncology, immunology and other disease areas. - Degrader programs are harder to run than conventional small-molecule projects because they require coordinated decisions across biology, chemistry, DMPK and development. - An integrated CRO model can reduce handoff delays, preserve technical context and help teams spot liabilities earlier. - Earlier attention to manufacturability, formulation and scale-up risk can lower avoidable time and cost.

What happened: - WuXi AppTec outlined integrated capabilities for protein degrader development in a Sept. 21, 2026 announcement from San Diego. - The company framed its CRDMO model as a connected platform for discovery, development and manufacturing. - WuXi AppTec said the platform is designed to support targeted protein degrader programs as they move from early discovery toward clinical readiness.

The details: - Targeted protein degradation removes disease-causing proteins by directing them to the cell’s own degradation machinery, including the ubiquitin–proteasome system. - PROTACs and molecular glues often require coordinated expertise in biology, medicinal chemistry, DMPK, analytical sciences, formulation and manufacturing. - Degrader discovery can require simultaneous optimization of degradation efficiency, selectivity, permeability, solubility, metabolic stability and in vivo exposure. - Protein degraders can include bifunctional molecules, macrocycles, chiral centers and specialized linker architectures. - Candidate selection needs to weigh potency alongside PK, selectivity, manufacturability and translational potential. - Process chemistry, analytical methods, formulation and scale-up feasibility need early review. - WuXi AppTec said its discovery work connects chemistry and biology for hit identification and lead optimization. - Discovery support can include degrader design, linker strategy, E3 ligase ligand optimization, protein degradation assays, target engagement studies and structure–activity relationship refinement. - Dr. Tao Guo, senior vice president, Research Chemistry Services, Integrated Program Management at WuXi AppTec, described discovery chemistry as an increasingly integrated function that works alongside biology from the start of a program. - As programs advance, WuXi AppTec said it supports chemistry, manufacturing and controls development together with DMPK studies. - Later-stage work can include process optimization, analytical development, formulation strategies, drug exposure analysis, tissue distribution, metabolic pathways and PK/PD relationships.

Between the lines: - The announcement is as much a pitch for a workflow as it is for a service menu. - The core message is that degrader programs can fail on execution, not just on biology, so the service model needs to span discovery through scale-up. - For smaller biotech companies, a single external partner can provide continuity that internal teams may not have. - WuXi AppTec is positioning itself as that kind of partner for programs that need broad scientific coordination.

What's next: - WuXi AppTec is likely to keep emphasizing end-to-end support as targeted protein degradation matures. - Programs in this space will continue to depend on integrated biology, chemistry, DMPK and CMC decisions to reach the clinic. - The company said its approach is intended to support programs from early design through process optimization and clinical readiness.

The bottom line: - WuXi AppTec is betting that the winning protein degrader partner is not just a synthesis shop, but a connected platform that can carry a program from discovery to development.